US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

2.09

+0.06002.96%

Post-market: 2.090.00000.00%19:31 EDT

Volume:195.83K

Turnover:406.03K

Market Cap:132.88M

PE:-3.85

High:2.10

Open:2.05

Low:2.04

Close:2.03

52wk High:3.43

52wk Low:0.4100

Shares:63.58M

Float Shares:39.66M

Volume Ratio:1.21

T/O Rate:0.49%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5428

EPS(LYR):-0.6272

ROE:-161.39%

ROA:-58.43%

PB:7.29

PE(LYR):-3.33

Loading ...

Overview Company News Filings

TuHURA Biosciences initiated with an Outperform at Citizens

Tuhura Biosciences Inc - Credit Facility Expected to Fund Ifx-2.0 Phase 3 and Tbs-2025 Milestones

THOMSON REUTERS

Tuhura Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway Into 2028

THOMSON REUTERS

Press Release: TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

BRIEF-Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.

Tuhura Biosciences Inc - Enters at the Market Offering Agreement With H.c. Wainwright & Co. - SEC Filing

THOMSON REUTERS

Tuhura Biosciences Inc - May Offer Common Stock up to $50 Mln Aggregate - SEC Filing

THOMSON REUTERS

Tuhura Biosciences raises $12.6 million in unregistered private placement of shares, warrants

Tuhura Biosciences Appoints Amanda Garofalo, Mshs, as Senior Vice President of Clinical Operations

THOMSON REUTERS

Press Release: TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

BRIEF-Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate Update

TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate

Benzinga Earnings

Press Release: TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences FY25 net loss widens to $30 million

These 16 stocks are a short seller's dream - likely losers no matter what the market does

TuHURA Biosciences Inc expected to post a loss of 13 cents a share - Earnings Preview

These 16 stocks are a short seller's dream - likely losers no matter what the market does

TuHURA Biosciences names Craig Tendler to CMO-like role while he remains on board

Press Release: Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/HURA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.09,"timestamp":1789675200000,"preClose":2.03,"halted":0,"volume":195831,"hourTrading":{"tag":"盘后","latestPrice":2.09,"preClose":2.09,"latestTime":"19:31 EDT","volume":36,"amount":75.7342,"timestamp":1789687877885,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02955665024630545,"floatShares":39657200,"shares":63578528,"eps":-0.542788,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"09-17 16:00:00 EDT","open":2.05,"high":2.1,"low":2.04,"amount":406034.68333230005,"amplitude":0.029557,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.542788,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.03,"preHourTrading":{"tag":"盘前","latestPrice":2.0171,"preClose":2.03,"latestTime":"07:43 EDT","volume":174,"amount":350.97832320000003,"timestamp":1789645399115,"change":-0.0129,"changeRate":-0.006355,"amplitude":0.001429},"postHourTrading":{"tag":"盘后","latestPrice":2.09,"preClose":2.09,"latestTime":"19:31 EDT","volume":36,"amount":75.7342,"timestamp":1789687877885,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.211887},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":39657200,"roa":"-58.43%","roe":"-161.39%","lyrEps":-0.627208,"volumeRatio":1.211887,"shares":63578528,"dividePrice":0,"high":2.1,"amplitude":0.029557,"preClose":2.03,"low":2.04,"week52Low":0.41,"pbRate":"7.29","week52High":3.43,"institutionHeld":0,"latestPrice":2.09,"eps":-0.542788,"divideRate":0,"volume":195831,"delay":0,"ttmEps":-0.542788,"open":2.05,"prevYearClose":0.7567,"prevWeekClose":2.05,"prevMonthClose":2.13,"prevQuarterClose":2.34,"fiveDayClose":2.03,"twentyDayClose":2.28,"sixtyDayClose":2.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HURA","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-15","symbol":"HURA","fiscalQuarterEnding":"2026/03","expectedEps":-0.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2026-03-31","symbol":"HURA","fiscalQuarterEnding":"2025/12","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1777348800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-09-16","current":-3.85049,"percent":0.754797,"low":-15.284879,"twenty":-7.623111,"median":-4.754993,"eighty":-4.045834,"high":-0.912265,"avg":-5.485591,"sd":2.633963,"marketCap":129365032},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-20","current":-2.301396,"twenty":-8.352484,"median":-5.119354,"eighty":-3.87886,"marketCap":67399763},{"date":"2026-02-27","current":-3.358794,"twenty":-8.340447,"median":-5.054798,"eighty":-3.490101,"marketCap":98367222},{"date":"2026-03-06","current":-3.234394,"twenty":-8.312748,"median":-5.017712,"eighty":-3.42514,"marketCap":94723992},{"date":"2026-03-13","current":-4.063726,"twenty":-8.270771,"median":-4.990628,"eighty":-3.42514,"marketCap":119012195},{"date":"2026-03-20","current":-3.71126,"twenty":-8.265757,"median":-4.95929,"eighty":-3.463659,"marketCap":108689709},{"date":"2026-03-27","current":-4.042992,"twenty":-8.259713,"median":-4.911411,"eighty":-3.465457,"marketCap":118404990},{"date":"2026-04-02","current":-3.427302,"twenty":-8.251655,"median":-4.911411,"eighty":-3.465457,"marketCap":102997215},{"date":"2026-04-10","current":-4.146613,"twenty":-8.215999,"median":-4.888063,"eighty":-3.434334,"marketCap":124613914},{"date":"2026-04-17","current":-6.262232,"twenty":-8.188482,"median":-4.911411,"eighty":-3.463059,"marketCap":188192442},{"date":"2026-04-24","current":-4.844767,"twenty":-8.114171,"median":-4.911411,"eighty":-3.465457,"marketCap":145594829},{"date":"2026-05-01","current":-4.738986,"twenty":-8.030053,"median":-4.911411,"eighty":-3.469004,"marketCap":142415902},{"date":"2026-05-08","current":-5.077485,"twenty":-7.995389,"median":-4.911411,"eighty":-3.486647,"marketCap":152588467},{"date":"2026-05-15","current":-5.310203,"twenty":-7.976007,"median":-4.911411,"eighty":-3.500461,"marketCap":159582105},{"date":"2026-05-22","current":-4.818786,"twenty":-7.933354,"median":-4.916581,"eighty":-3.501154,"marketCap":149017115},{"date":"2026-05-29","current":-4.839379,"twenty":-7.917237,"median":-4.916581,"eighty":-3.503927,"marketCap":149653940},{"date":"2026-06-05","current":-4.509889,"twenty":-7.897092,"median":-4.911411,"eighty":-3.58686,"marketCap":139464736},{"date":"2026-06-12","current":-4.509889,"twenty":-7.897092,"median":-4.904697,"eighty":-3.677385,"marketCap":139464736},{"date":"2026-06-18","current":-4.571669,"twenty":-7.864858,"median":-4.888063,"eighty":-3.704485,"marketCap":141375212},{"date":"2026-06-26","current":-5.333613,"twenty":-7.8568,"median":-4.908236,"eighty":-3.727846,"marketCap":164937747},{"date":"2026-07-02","current":-5.04531,"twenty":-7.856579,"median":-4.901158,"eighty":-3.744433,"marketCap":156022193},{"date":"2026-07-10","current":-4.818786,"twenty":-7.844566,"median":-4.888063,"eighty":-3.771996,"marketCap":149017115},{"date":"2026-07-17","current":-4.571669,"twenty":-7.81248,"median":-4.891607,"eighty":-3.786112,"marketCap":141375212},{"date":"2026-07-24","current":-4.427517,"twenty":-7.760101,"median":-4.868044,"eighty":-3.812345,"marketCap":136917435},{"date":"2026-07-31","current":-4.468703,"twenty":-7.71981,"median":-4.860726,"eighty":-3.856706,"marketCap":138191085},{"date":"2026-08-07","current":-4.355441,"twenty":-7.692662,"median":-4.839379,"eighty":-3.914446,"marketCap":134688546},{"date":"2026-08-14","current":-4.736413,"twenty":-7.681875,"median":-4.818786,"eighty":-3.97155,"marketCap":146469814},{"date":"2026-08-21","current":-4.616534,"twenty":-7.672382,"median":-4.818786,"eighty":-4.019886,"marketCap":141375212},{"date":"2026-08-28","current":-4.432444,"twenty":-7.669558,"median":-4.813895,"eighty":-4.020835,"marketCap":135737694},{"date":"2026-09-04","current":-4.370015,"twenty":-7.66133,"median":-4.7776,"eighty":-4.030552,"marketCap":133825895},{"date":"2026-09-11","current":-4.224348,"twenty":-7.647286,"median":-4.769319,"eighty":-4.043702,"marketCap":129365032},{"date":"2026-09-16","current":-4.224348,"twenty":-7.623111,"median":-4.754993,"eighty":-4.045834,"marketCap":129365032}],"updateTime":1789712532793},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630699933","title":"TuHURA Biosciences initiated with an Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2630699933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630699933?lang=en_us&edition=fundamental","pubTime":"2026-04-27 16:45","pubTimestamp":1777279556,"startTime":"0","endTime":"0","summary":"Citizens initiated coverage of TuHURA Biosciences (HURA) with an Outperform rating and $9 price target TuHURA is a clinical-stage immuno-oncology c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629304364","title":"Tuhura Biosciences Inc - Credit Facility Expected to Fund Ifx-2.0 Phase 3 and Tbs-2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2629304364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629304364?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA2CZK8P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043653","title":"Tuhura Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043653?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA2CZK8P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043963","title":"Press Release: TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043963","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043963?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857400,"startTime":"0","endTime":"0","summary":"Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones. TAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses.  The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC.TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome prim","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","HURA","BK4139","R","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627845222","title":"TuHURA Biosciences initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2627845222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627845222?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:20","pubTimestamp":1776255648,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $7 price target The firm’s target is based on its estimate o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626077922","title":"BRIEF-Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2626077922","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626077922?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:38","pubTimestamp":1775680730,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co. April 8  - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INC - ENTERS AT THE MARKET OFFERING AGREEMENT WITH H.C. WAINWRIGHT & CO. - SEC FILINGTUHURA BIOSCIENCES INC - MAY OFFER COMMON STOCK UP TO $50 MILLION AGGREGATE - SEC FILINGSource text: [ID:n0001193125-26-147748]Further company coverage: HURA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R1A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626922274","title":"Tuhura Biosciences Inc - Enters at the Market Offering Agreement With H.c. Wainwright & Co. - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2626922274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626922274?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:33","pubTimestamp":1775680439,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R1A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626227089","title":"Tuhura Biosciences Inc - May Offer Common Stock up to $50 Mln Aggregate - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2626227089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626227089?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:33","pubTimestamp":1775680439,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R1A5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626922668","title":"Tuhura Biosciences raises $12.6 million in unregistered private placement of shares, warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626922668","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626922668?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:17","pubTimestamp":1775679478,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences completed June 2025 private placement tied to Kineta merger condition, issuing 4,759,309 common shares with matching warrants.Gross offering amount totaled USD 12.6 million at combined unit price USD 2.65 per share-warrant unit.Net proceeds were USD 11.5 million, reflecting USD 1.1 million equity issuance costs.Warrants carry exercise price USD 3.31 per share, expiring Dec. 3, 2030.Financing priced at 15% discount to Nasdaq closing price for TuHURA shares on June 2, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Excha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL91GBBf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625193723","title":"Tuhura Biosciences Appoints Amanda Garofalo, Mshs, as Senior Vice President of Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2625193723","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625193723?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:45","pubTimestamp":1775562300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA2RGNJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625993725","title":"Press Release: TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2625993725","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625993725?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:45","pubTimestamp":1775562300,"startTime":"0","endTime":"0","summary":"Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development. TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Amanda Garofalo, MSHS, as Senior Vice President  of Clinical Operations.Mrs. Garofalo, who brings over 20 years of clinical and development experience, will work closely with Craig Tendler, M.D., and oversee day-to-day clinical operations.TuHURA Biosciences, Inc.  is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of pat","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4232","BK4022","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513567","title":"BRIEF-Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513567?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:04","pubTimestamp":1775045053,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate UpdateApril 1 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES REPORTS FOURTH ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA7NGFYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518441","title":"TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518441","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518441?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:52","pubTimestamp":1775044358,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 3.7 percent. This is a 90.51 percent increase over losses of $(1.37) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51594849/tuhura-biosciences-q4-eps-0-13-beats-0-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518970","title":"Press Release: TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518970","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518970?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:45","pubTimestamp":1775043900,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update.Dr. Bianco continued, \"We are grateful to have the unwavering support of our shareholders, who are committed to supporting our programs and realizing the potentially meaningful opportunity each one addresses.\". -- Initiated a randomized Phase 3 Accelerated Approval Trial for IFx-2.0 in. first line treatment of patients with advanced or metastatic Merkel Cell. Phase 3 study trial being conducted under a Special Protocol Assessment.  agreement with U.S. Food and Drug Administration . Primary. endpoint of Overall Response Rate  qualifies for accelerated. approval process. Key secondary endpoint of Progression Free Survival.  may satisfy the requirement for a post confirmator","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","BK4161","LU2023250843.SGD","LU2360032135.SGD","ORR","LU0058720904.USD","SG9999002232.USD","LU2361044865.SGD","LU0130102774.USD","LU0203347892.USD","SG9999002224.SGD","LU1934455194.USD","LU1941712348.USD","IE00B2B36J28.USD","LU0477156953.USD","IR","LU1061106388.HKD","LU1116320901.HKD","LU1929549753.HKD","LU1974910355.USD","IE00BBT3K403.USD","LU2361045086.USD","LU0417517546.SGD","IE00B1BXHZ80.USD","BK4533","ADC","SG9999015341.SGD","LU1057294990.SGD","LU1066051225.USD","LU2125154935.USD","LU1066051811.HKD","LU1430594728.SGD","HURA","LU0985320562.USD","R","IE00BN8TJ469.HKD","BK4585","SG9999014542.SGD","BK4231","IE00BSNM7G36.USD","LU0208291251.USD","IE00B4R5TH58.HKD","LU0098860793.USD","SGXZ57979304.SGD","PFS","LU1037948897.HKD","LU0965509101.SGD","LU0868494617.USD","MRK","LU2125154778.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553904","title":"TuHURA Biosciences FY25 net loss widens to $30 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553904","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553904?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:16","pubTimestamp":1774991817,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences posted fiscal 2025 net loss of $30 million.Cash and cash equivalents ended year at $4 million.Funding runway was projected to extend through second quarter into third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL8vqvDq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387604","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387604?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:04","pubTimestamp":1774717440,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLYX","CV","BK4023","EVCM","CRDF","BK4608","BK4138","BK4139","BK4548","BK4161","BK4603","SLS","BK4144","BK4604","BK4116","NNE","ATLN","HURA","GETY","BK4082","NNEX","SERV","BK4008","CD","NFE","BK4606","RXT","BK4077","LCID","PDYN","BK4212","BK4182","BYND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622805616","title":"TuHURA Biosciences Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622805616","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622805616?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:35","pubTimestamp":1774647306,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc  expected to post a loss of13cents a share - Earnings Preview TuHURA Biosciences Inc HURA.OQ HURA.O is expected to  report resultson March 31 (estimated) for the period ending D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F253:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826019","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826019?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:05","pubTimestamp":1774613100,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4606","BK4116","NNEX","BK4608","CRDF","FLYX","BK4077","NFE","BK4603","BK4138","SLS","BK4182","BK4604","EVCM","BK4548","HURA","ATLN","BK4144","GETY","CD","LCID","BK4082","SERV","BK4212","BK4023","NNE","PDYN","BK4139","BYND","CV","BK4008","BK4161","RXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708657","title":"TuHURA Biosciences names Craig Tendler to CMO-like role while he remains on board","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708657","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708657?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:46","pubTimestamp":1774266380,"startTime":"0","endTime":"0","summary":"TuHURA said Craig Tendler will provide strategic and operational services consistent with those of a chief medical officer while continuing as a board member.He will oversee clinical development strategy and operations for the pipeline, including the VISTA-inhibiting antibody TBS-2025.Tendler previously served as Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs at Johnson & Johnson Innovative Medicine Research & Development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9jMBr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU1221951129.SGD","LU0345770993.USD","LU1066051811.HKD","SG9999002232.USD","LU1066051225.USD","LU1074936037.SGD","IE00BLSP4452.SGD","IE00BLSP4239.USD","HURA","LU0203347892.USD","LU0985320562.USD","IE00BGHQF631.EUR","LU0689626769.HKD","LU1244550577.SGD","LU0795875086.SGD","IE00BDGV0183.EUR","LU2468319806.SGD","LU2129689431.USD","BK4139","BK4532","LU0114720955.EUR","LU0289739699.SGD","LU0640476718.USD","LU2505996509.AUD","LU0795875169.SGD","LU1732799900.SGD","LU0683600562.USD","IE00BFXG1179.USD","LU0889566641.SGD","LU1496350502.SGD","BK4581","LU1280957306.USD","LU0098860793.USD","BK4588","LU1066051498.USD","LU1023059063.AUD","LU2430703095.HKD","LU1267930813.SGD","IE00BJT1NW94.SGD","JNJ","SG9999002224.SGD","IE00B19Z3B42.SGD","IE0034235303.USD","IE0009355771.USD","IE00BBT3K403.USD","LU2347655156.SGD","IE00BVYPNV92.GBP","LU0432979614.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621641708","title":"Press Release: Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621641708","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621641708?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:45","pubTimestamp":1774266300,"startTime":"0","endTime":"0","summary":"Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology. Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales. Dr. Tendler, a distinguished thirty-year industry veteran, will provide strategic and operational services consistent with those of a CMO while continuing his role as a member on the TuHURA Board of Directors. Dr. Tendler is a seasoned professional, previously serving as the Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs of Johnson & Johnson Innovative Medicine Research","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU1221951129.SGD","LU0124676726.USD","LU1066053197.SGD","LU0889566641.SGD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4504","IE00BJT1NW94.SGD","LU1221951046.USD","LU1244550494.USD","LU0792757196.USD","LU1280957306.USD","JNJ","LU0640476718.USD","LU1032955483.USD","IE0001KFT4U8.USD","LU2602419157.SGD","LU1032466523.USD","LU1059921491.USD","SG9999001440.SGD","LU2129689514.USD","LU2129689605.HKD","LU2089984988.USD","LU2592432038.USD","BK4568","IE00B1BXHZ80.USD","LU1929549753.HKD","LU2129689431.USD","LU1894683348.USD","LU1066051498.USD","LU1196500208.SGD","LU0289739699.SGD","BK4007","HURA","R","LU1162221912.USD","LU1496350502.SGD","LU1894683264.USD","LU0203347892.USD","IE00BDGV0183.EUR","IE00B4R5TH58.HKD","LU0466842654.USD","LU2468319806.SGD","LU0098860793.USD","LU0203345920.USD","LU1261432733.SGD","LU1585245621.USD","IE0034235303.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}]}}